Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Bladder cancer is the sixth most prevalent malignancy in the United States and causes more
than 16,000 deaths annually. The most common clinical presentation is asymptomatic …

Background The extent of lymph node dissection (LND) in bladder cancer (BCa) patients at
the time of radical cystectomy may affect oncologic outcome. Objective To evaluate whether …

Single-cell sequencing technologies have noteworthily improved our understanding of the
genetic map and molecular characteristics of bladder cancer (BC). Here we identify CD39 as …

In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …